default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Medipost wins patent for Cartistem in Mexico

Lee Han-soo  Published 2018.07.11  15:41  Updated 2018.07.11 15:45

공유
default_news_ad2

Medipost said Wednesday that it has acquired patents in Mexico on its core production technology of Cartistem.

Cartistem is the world’s first cord blood-derived mesenchymal stem cell treatment, which won the marketing license from the Ministry of Food and Drug Safety in January 2012.

The patent, named “TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof,” relates to a technology for preventing or treating cartilage damage, degeneration, deficiency, and degenerative arthritis. The patent also includes cord blood-derived mesenchymal stem cells expressing TSP-2 protein composition.

MediPost acquired 10 domestic and foreign patents related to stem cell treatment drugs last year and is actively involved in research and development (R&D) to secure future-oriented core technologies, the company said.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch